CHA University clinical trials
CHA University is the lead sponsor of 14 current clinical trials in our South Korea, India and Italy registers. 10 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Lenvatinib, Atezolizumab and Autologous Platelet-Rich Plasma (PRP). The most-studied condition is Biliary Tract Cancer.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by CHA University
14 on ClinicalTrials.govRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in CHA University trials
7 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in CHA University trials
16 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in South Korea | 14 | 10 |
| Clinical trials in India | 1 | 1 |
| Clinical trials in Italy | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Other sponsors in Biliary Tract Cancer
| Sponsor | Trials |
|---|---|
| ModeX Therapeutics, An OPKO Health Company | 1 |
| Zhai Wenlong | 1 |
Sponsors with the most current trials registered for this condition.
Questions about CHA University trials
How many clinical trials does CHA University sponsor?
CHA University is the lead sponsor of 14 current trials on ClinicalTrials.gov in our South Korea, India and Italy registers, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.
Are CHA University trials recruiting?
Yes. 10 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is CHA University testing?
Its current trials name 7 drugs and biologicals as interventions. The most frequent are Lenvatinib (2), Atezolizumab (1), Autologous Platelet-Rich Plasma (PRP) (1), Bevacizumab (1) and Colchicine (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.